教师内容页
 |
祭美菊 |
研究领域（方向）
1) 肿瘤遗传与表观遗传学
2) 肿瘤早期诊断与个体化治疗
3) 肿瘤分子靶向治疗
个人及工作简历
祭美菊，女，1974年，副研究员。2001年毕业于兰州大学生命科学学院，获得理学硕士。2001年9月进入东南大学生物医学工程学院攻读博士学位。2005年至2008年分别在东南大学及美国约翰·霍普金斯大学医学院从事博士后研究。现为西安交通大学医学院第一附属医院副研究员，主要从事肿瘤遗传与表观遗传学研究，近年来先后主持国家自然科学基金4项、中国博士后基金1项，共发表学术论文40篇，其中以第一作者（包含并列第一作者）及通讯作者发表SCI论文15篇，影响因子超过55。
科研项目
1) 国家自然科学基金 (2015.1-2018.12, 项目编号：81472622)
2) 国家自然科学基金 (2013.1-2016.12, 项目编号：81272933)
3) 国家自然科学基金 (2010.1-2012.12, 项目编号：30973372)
4) 国家自然科学基金 (2007.1-2009.12, 项目编号：30600736)
5) 西安交通大学基本科研业务费"学科综合交叉类项目"
6) 中国博士后基金（2006.1-2007.12，项目编号：20060390954)
学术及科研成果、专利、论文
代表论文（*通讯作者）
1) Wang L, Tian L, Yang Q, Li H, Guan H, Shi B, Hou P, Ji M*. Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget. 2015 (In press) (IF: 6.359)
2) Cui B, Yang Q, Guan H, Shi B, Hou P, Ji M*. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 6.209)
3) Zhang Y, Qu Y, Gao K, Yang Q, Shi B, Hou P, Ji M*.High copy number of mitochondrial DNA (mtDNA) predicts good prognosis in glioma patients. Am J Cancer Res. 2015; 5(3):1207-16. (IF: 4.165)
4) Shao Y, Qu Y, Dang S, Yao B, Ji M*. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int. 2013; 13(1):51. (IF: 2.766)
5) Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M*. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci. 2012;13:4714-26. (IF: 2.862)
6) Joseph B#, Ji M#, Liu D, Hou P, Xing M. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007; 92:4766-70. (#并列第一作者；IF: 6.209)
7) Wang Y#, Ji M#, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J, Xing M. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 2008; 15:183-90. (#并列第一作者；IF: 4.805)
8) Hou P#, Ji M#, Yang B, Chen Z, Qiu J, Shi X, Lu Z. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 2006; 106:1602-9. (#并列第一作者；IF: 4.889)
9) Ji M, Zhang Y, Shi B, Hou P. Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol. 2011; 6:48. (IF: 2.597)
10) Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer. 2011; 11:147. (IF: 3.362)
11) Ji M, Hou P, Li S, He N, Lu Z. Microarray-based method for genotyping of functional single nucleotide polymorphisms using dual-color fluorescence hybridization. Mutat Res. 2004; 548:97-105. (IF: 3.68)
12) Ji M, Hou P, Li S, He N, Lu Z. Colorimetric silver detection of methylation using DNA microarray coupled with linker-PCR. Clin Chim Acta. 2004; 342:145-53. (IF: 2.824)
1) Wang L, Tian L, Yang Q, Li H, Guan H, Shi B, Hou P, Ji M*. Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget. 2015 (In press) (IF: 6.359)
2) Cui B, Yang Q, Guan H, Shi B, Hou P, Ji M*. PRIMA-1, a Mutant p53 Reactivator, Restores the Sensitivity of TP53 Mutant-type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep). J Clin Endocrinol Metab. 2014; 99(6):E962-70. (IF: 6.209)
3) Zhang Y, Qu Y, Gao K, Yang Q, Shi B, Hou P, Ji M*.High copy number of mitochondrial DNA (mtDNA) predicts good prognosis in glioma patients. Am J Cancer Res. 2015; 5(3):1207-16. (IF: 4.165)
4) Shao Y, Qu Y, Dang S, Yao B, Ji M*. MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int. 2013; 13(1):51. (IF: 2.766)
5) Shi J, Yao D, Liu W, Wang N, Lv H, He N, Shi B, Hou P, Ji M*. Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci. 2012;13:4714-26. (IF: 2.862)
6) Joseph B#, Ji M#, Liu D, Hou P, Xing M. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors. J Clin Endocrinol Metab. 2007; 92:4766-70. (#并列第一作者；IF: 6.209)
7) Wang Y#, Ji M#, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J, Xing M. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 2008; 15:183-90. (#并列第一作者；IF: 4.805)
8) Hou P#, Ji M#, Yang B, Chen Z, Qiu J, Shi X, Lu Z. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 2006; 106:1602-9. (#并列第一作者；IF: 4.889)
9) Ji M, Zhang Y, Shi B, Hou P. Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol. 2011; 6:48. (IF: 2.597)
10) Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer. 2011; 11:147. (IF: 3.362)
11) Ji M, Hou P, Li S, He N, Lu Z. Microarray-based method for genotyping of functional single nucleotide polymorphisms using dual-color fluorescence hybridization. Mutat Res. 2004; 548:97-105. (IF: 3.68)
12) Ji M, Hou P, Li S, He N, Lu Z. Colorimetric silver detection of methylation using DNA microarray coupled with linker-PCR. Clin Chim Acta. 2004; 342:145-53. (IF: 2.824)
联系方式
电子邮箱：mjji0409@163.com
